Drug disappoints in recurrent glioblastoma
5 February 2010
| by Nicola Garrett
Hopes for treating recurrent glioblastoma with the targeted anti-angiogenic enzastaurin have been dashed by disappointing phase III results....
Want to read complete article? Please Sign in or Register.